Chemren Bio-Engineering Co., Ltd.

MBX-2982 is a selective, orally-available GPR119 agonist for the treatment of type 2 tiabetes.
IC50 value:
Target: GPR119
MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.

[1]. BRIAN ROBERTS, FRANCINE M. GREGOIRE, DAVID B. KARPF et al. MBX-2982, a Novel Oral GPR119 Agonist for the Treatment of Type 2 Diabetes: Results of Single & Multiple Dose Studies.

[2]. Gater D. 32nd National Medicinal Chemistry Symposium--medicinal chemistry developments for neurodegeneration, diabetes and cancer. Drugs. 2010 Aug;13(8):514-6.

[3]. Jones RM, Leonard JN, Buzard DJ, Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59.